Clinical Trials /

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

NCT02863991

Description:

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma. Funding Source - FDA OOPD

Related Conditions:
  • Multiple Myeloma
Recruiting Status:

Active, not recruiting

Phase:

Phase 1/Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Oral ONC201 in Relapsed/Refractory Multiple Myeloma
  • Official Title: Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Clinical Trial IDs

  • ORG STUDY ID: ONC007
  • SECONDARY ID: R01FD005402
  • NCT ID: NCT02863991

Conditions

  • Multiple Myeloma

Interventions

DrugSynonymsArms
ONC201ONC201

Purpose

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma. Funding Source - FDA OOPD

Trial Arms

NameTypeDescriptionInterventions
ONC201ExperimentalSingle agent ONC201.
  • ONC201

Eligibility Criteria

        Inclusion Criteria:

          1. Patients must be refractory to, or not a candidate for, established therapy known to
             provide clinical benefit for their malignancy.

          2. Measurable disease M protein component in serum (at least 0.5 g/dL) and/or urine (if
             present) (>=0.2 g excreted in a 24 hour collection sample).

          3. All previous therapies for cancer, including radiotherapy, major surgery and
             investigational therapies discontinued for ≥ 14 days (≥ 28 days for mitomycin C or
             nitrosoureas) before study entry, and all acute effects of any prior therapy resolved
             to baseline severity or Grade ≤ 1 Common Terminology Criteria for Adverse Events
             (CTCAE v4.03), except alopecia or parameters defined in this eligibility list.

          4. Age ≥ 18 years.

          5. ECOG performance status ≤ 1.

          6. Adequate organ and marrow function as defined below:

               1. Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to
                  treatment (cycle 1 day 1, C1D1)

               2. Platelets ≥75,000/mm3 without platelet transfusion ≤ 3 days prior to C1D1

               3. Hemoglobin >8.0 mg/dL without red blood cell transfusion ≤ 3 days prior to C1D1

               4. Total serum bilirubin <1.5 X upper limit of normal (ULN)

               5. AST (SGOT)/ALT (SGPT) ≤2 X ULN; ≤ 5 X ULN if there is liver involvement secondary
                  to tumor

               6. Serum creatinine ≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2)

               7. Serum or urine pregnancy test (for females of childbearing potential) negative ≤7
                  days of starting treatment

          7. Ability to understand and the willingness to sign a written informed consent document
             and comply with the study scheduled visits, treatment plans, laboratory tests and
             other procedures.

          8. Female patients must be surgically sterile or be postmenopausal, or must agree to use
             effective contraception during the period of the trial and for at least 90 days after
             completion of treatment. Male patients must be surgically sterile or must agree to use
             effective contraception during the period of the trial and for at least 90 days after
             completion of treatment. The decision of effective contraception will be based on the
             judgment of the principal investigator or a designated associate.

        Exclusion Criteria:

          1. Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to
             underlying malignancy or prior related treatment) or history of abdominal fistula,
             gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within
             6 months prior to study enrollment. Gastroesophageal reflux disease under treatment
             with proton pump inhibitors is allowed.

          2. Pregnancy or breast feeding.

          3. Current active treatment in another clinical study.

          4. Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C
             (HCV)

          5. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)-related illness that is not well controlled.

          6. Active or prior plasma cell leukemia (defined as either 20% of peripheral WBC
             comprised of plasma/CD138+ cells or an absolute count of 2 x 10^9/L).

          7. Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma
             cell dyscrasia.

          8. Subjects with serum calcium (corrected for albumin) ≥ 12 mg/dL

          9. Any of the following in the previous 6 months: myocardial infarction, severe/unstable
             angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
             cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.

         10. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, or in
             the judgment of the investigator would make the patient inappropriate for entry into
             the study.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Overall response rate
Time Frame:3 years
Safety Issue:
Description:Best overall response

Details

Phase:Phase 1/Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Oncoceutics, Inc.

Last Updated

April 23, 2019